COLUCID PHARMACEUTICALS
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
COLUCID PHARMACEUTICALS
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2005-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.colucid.com
Total Employee:
1+
Status:
Active
Contact:
(919) 649-6184
Email Addresses:
[email protected]
Total Funding:
97.3 M USD
Technology used in webpage:
Font Awesome Amazon Google Maps Google Maps API ASP.NET Amazon Ohio Region Ninja Forms Entrust EV Entrust SSL Omniture SiteCatalyst
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Domain Associates
Domain Associates investment in Series C - CoLucid Pharmaceuticals
TVM Capital Life Science
TVM Capital Life Science investment in Series C - CoLucid Pharmaceuticals
Novo Ventures
Novo Ventures investment in Series C - CoLucid Pharmaceuticals
Care Capital
Care Capital investment in Series C - CoLucid Pharmaceuticals
Auriga Partners
Auriga Partners investment in Series C - CoLucid Pharmaceuticals
Pearl Street Venture Funds
Pearl Street Venture Funds investment in Series C - CoLucid Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Series C - CoLucid Pharmaceuticals
Triathlon Medical Venture Partners
Triathlon Medical Venture Partners investment in Series C - CoLucid Pharmaceuticals
Domain Associates
Domain Associates investment in Venture Round - CoLucid Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Venture Round - CoLucid Pharmaceuticals
Official Site Inspections
http://www.colucid.com
- Host name: redirector.1brandsight.net
- IP address: 18.217.251.129
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "CoLucid Pharmaceuticals"
CoLucid Pharmaceuticals - Crunchbase Company Profile & Funding
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine …See details»
colucid.com Company Profile | Management and Employees List
Colucid.com Profile and History. colucid.com is a company that operates in the Financial Services industry. It employs 21-50 people and has $1M-$5M of revenue.See details»
CoLucid Pharmaceuticals, Inc | LinkedIn
CoLucid Pharmaceuticals, Inc | 378 followers on LinkedIn. CoLucid is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache …See details»
CoLucid Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. CoLucid Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
CoLucid Pharmaceuticals - Company Profile - Tracxn
Sep 24, 2024 CoLucid Pharmaceuticals - Developer of therapies for central nervous system disorders. Acquired by Lilly. Raised a total funding of $96M over 5 rounds from 10 investors. …See details»
colucid.com - Overview, News & Similar companies - ZoomInfo
View colucid.com (www.colucid.com) location , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
CoLucid Pharmaceuticals - PitchBook
When was CoLucid Pharmaceuticals founded? CoLucid Pharmaceuticals was founded in 2005. Where is CoLucid Pharmaceuticals headquartered? CoLucid Pharmaceuticals is …See details»
CoLucid Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. 2520 Meridian Parkway Suite 400. Durham, North Carolina, 27713, United States. 919-649-6184See details»
CoLucid Pharmaceuticals - VentureRadar
CoLucid was founded by Pappas Ventures and is developing oral Lasmiditan for the acute treatment of migraine headache and intravenous Lasmiditan for... ... Find out ...See details»
Lucidchart | Diagramming Powered By Intelligence
Equip every team in your organization with the most used, most intelligent, most complete, and most connected platform of its kind. Learn more. Additional resources. AI in Lucid. Learn more …See details»
Lilly Completes Acquisition of CoLucid Pharmaceuticals
CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute ...See details»
Emerging Drug Developer: CoLucid | Fierce Biotech
Jul 14, 2008 CoLucid A roster of new biotech companies has sprung up recently that relies on a virtual business model to keep costs down as theySee details»
Lucidchart - Wikipedia
Lucidchart is a web-based diagramming application [2] that allows users to visually collaborate on drawing, revising and sharing charts and diagrams, and improve processes, systems, and …See details»
Eli Lilly acquires CoLucid Pharmaceuticals for $960m
Mar 1, 2017 Eli Lilly and Company president and CEO David Ricks said: "We are pleased to announce the completion of our acquisition of CoLucid, which will enhance Lilly's existing pain …See details»
Eli Lilly to acquire US company CoLucid Pharmaceuticals for $960m
Jan 19, 2017 Eli Lilly president and CEO David Ricks said: "Lasmiditan is a novel, first-in-class molecule that could represent the first significant innovation for the acute treatment of migraine …See details»
Lilly buys migraine biotech CoLucid, and the drug it outlicensed, …
Jan 18, 2017 Eli Lilly says it will spend nearly $1 billion to buy out CoLucid Pharmaceuticals and get its hands on its late-stage acute migraine candidate, which Lilly outlicensed to the …See details»
Emerging Drug Developer: CoLucid | Fierce Biotech
CoLucid helps define lean and mean in biotech A roster of new biotech companies has sprung up recently that relies on a virtual business model to keep costs down as ...See details»
Lilly buys CoLucid for migraine drugs - Chemistry World
Eli Lilly has agreed to buy pain and migraine specialist CoLucid for around $960 million (£760 million). At the same time, the company will make 485 US field sales representatives …See details»
CoLucid Pharmaceuticals | VentureRadar
Similar Companies: Esco Life Sciences Singapore Privately Held Esco Lifesciences Group provides enabling technologies, products, and services for the life sciences and healthcare …See details»
Lilly Regains Key Migraine Drug With $960 Million CoLucid …
Jan 18, 2017 Eli Lilly will regain a late-stage migraine drug with its $960 million plan to acquire small-cap biotech CoLucid Pharmaceuticals ().The announcement sent CoLucid stock to a …See details»